Aimmune Therapeutics (AIMT) PT Set at $40.00 by Credit Suisse Group

Aimmune Therapeutics (NASDAQ:AIMT) received a $40.00 price objective from Credit Suisse Group in a note issued to investors on Friday. The firm presently has a “buy” rating on the biotechnology company’s stock. Credit Suisse Group’s target price points to a potential upside of 32.06% from the company’s previous close.

Other analysts have also recently issued research reports about the company. Cantor Fitzgerald set a $62.00 price objective on Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Monday, October 15th. Roth Capital set a $80.00 price objective on Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, October 9th. Wedbush started coverage on Aimmune Therapeutics in a research report on Wednesday, October 17th. They set a “buy” rating and a $72.00 price objective for the company. ValuEngine cut Aimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 7th. Finally, Stifel Nicolaus started coverage on Aimmune Therapeutics in a research report on Thursday, September 13th. They set a “hold” rating and a $33.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $50.70.

NASDAQ:AIMT opened at $30.29 on Friday. The firm has a market cap of $1.88 billion, a PE ratio of -11.61 and a beta of -0.10. Aimmune Therapeutics has a 52-week low of $24.56 and a 52-week high of $42.00.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.03. Research analysts forecast that Aimmune Therapeutics will post -3.64 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the stock. Jennison Associates purchased a new stake in Aimmune Therapeutics in the 3rd quarter valued at about $5,077,000. Emerald Mutual Fund Advisers Trust grew its holdings in Aimmune Therapeutics by 601.0% in the 4th quarter. Emerald Mutual Fund Advisers Trust now owns 282,355 shares of the biotechnology company’s stock valued at $5,209,000 after buying an additional 242,075 shares during the period. Emerald Advisers Inc. PA grew its holdings in Aimmune Therapeutics by 557.2% in the 4th quarter. Emerald Advisers Inc. PA now owns 270,358 shares of the biotechnology company’s stock valued at $4,988,000 after buying an additional 229,218 shares during the period. California State Teachers Retirement System grew its holdings in Aimmune Therapeutics by 1.4% in the 4th quarter. California State Teachers Retirement System now owns 20,593 shares of the biotechnology company’s stock valued at $380,000 after buying an additional 293 shares during the period. Finally, American Century Companies Inc. grew its holdings in Aimmune Therapeutics by 9.6% in the 4th quarter. American Century Companies Inc. now owns 90,205 shares of the biotechnology company’s stock valued at $1,664,000 after buying an additional 7,913 shares during the period. Hedge funds and other institutional investors own 78.16% of the company’s stock.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

See Also: Market Capitalization in the Stock Market

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply